A phase I/IIa first-in-human study of PM1003 (anti-PD-L1 x 4-1BB bispecific antibody) in patients with advanced solid tumors

被引：0
|
作者：
Xue, J. [1 ]
Sun, Y. [2 ]
Li, D. [3 ]
Guo, Y. [1 ]
机构：
[1] Shanghai East Hosp, Tongji Univ, Sch Med, Med Oncol, Shanghai, Peoples R China
[2] Shandong First Med Univ, Phase I Clin Study Dept, Canc Hosp, Jinan, Peoples R China
[3] Shandong First Med Univ, Med Oncol, Canc Hosp, Jinan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2175
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1036P
引用
收藏
页码：S629 / S629
页数：1
相关论文
共 50 条
  • [1] Phase I safety and preliminary efficacy of PM1003, a bispecific antibody targeting PD-L1 and 4-1BB, in patients with advanced solid tumors
    Xue, Junli
    Sun, Yuping
    Li, DaPeng
    Guo, Ye
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors
    Ku, G.
    Shen, L.
    Klempner, S. J.
    Pan, H.
    Kratz, J.
    Liang, X.
    Deng, Y.
    Kim, S.
    Wang, Z.
    Feller, L.
    Powderly, J.
    Dayyani, F.
    Schneider, R. E.
    Girda, E.
    Berlin, J. D.
    Spencer, K.
    Nguyen, M. T.
    Wang, V.
    Xu, C.
    Zhu, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S631 - S631
  • [3] First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors
    Papadopoulos, Kyriakos P.
    Harb, Wael
    Peer, Cody J.
    Hua, Qiong
    Xu, Siying
    Lu, Haolan
    Lu, Ni
    He, Yue
    Xu, Ting
    Dong, Ruiping
    Gong, John
    Liu, David
    ONCOLOGIST, 2021, 26 (09): : E1514 - E1525
  • [4] First-in-human phase I/II safety and preliminary efficacy of PM1032, a bispecific antibody targeting CLDN18.2 and 4-1BB, in patients with advanced solid tumors.
    Guo, Ye
    Wu, Lihua
    Li, Yong
    Wen, Jinhua
    Xue, Junli
    Wang, Zhuoyi
    Li, Pu
    Zhao, Wei
    Liu, Jingfeng
    Rao, Xi
    Li, Qun
    Xue, Liqiong
    Ge, Xiaoxiao
    Lin, Fengjuan
    Tang, Wenbo
    Zhou, Jiuli
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors
    Falchook, Gerald Steven
    LoRusso, Patricia
    Goldman, Jonathan W.
    El-Khoueiry, Anthony B.
    Tolcher, Anthony W.
    Xing, Yan
    Henry, Jason Timothy
    Keam, Bhumsuk
    Kim, Dong-Wan
    Kim, Tae-Yong
    Kim, Hye Ryun
    Hong, Min Hee
    Kim, Min Hwan
    Lee, Dae Ho
    Lee, SangMi
    Jeon, JuYeun
    Hayslip, John W.
    Xu, Cong
    Garon, Edward B.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] First-in-human, phase 1a, dose escalation study of BGB-B167, a CEA x 4-1BB bispecific antibody, as monotherapy or combined with tislelizumab (anti-PD-1), in patients with selected advanced or metastatic solid tumors
    Desai, Jayesh
    Frentzas, Sophia
    Fakih, Marwan
    Ameratunga, Malaka
    O'Neill, Siobhan
    Pelster, Meredith
    Stein, Brian N.
    Body, Amy
    Li, Bai
    Strauss, Ross M.
    Zhao, Yating
    Dong, Gaohong
    Cecchini, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 123 - 123
  • [7] Phase I study of anti-PD-L1 antibody MPDL3280A in patients with advanced solid tumors
    Murakami, Haruyasu
    Yamamoto, Noboru
    Kenmotsu, Hirotsugu
    Takahashi, Toshiaki
    Fujiwara, Yutaka
    Mizugaki, Hidenori
    Ishida, Yoshimasa
    Kawakami, Tomohisa
    ANNALS OF ONCOLOGY, 2015, 26 : 98 - 98
  • [8] A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors
    Naing, Aung
    Gelderblom, Hans
    Gainor, Justin F.
    Forde, Patrick M.
    Butler, Marcus
    Lin, Chia-Chi
    Sharma, Sunil
    de Olza, Maria Ochoa
    Schellens, Jan H. M.
    Soria, Jean-Charles
    Taylor, Matthew H.
    Silva, Antonio P.
    Li, Zhonggai
    Bilic, Sanela
    Cameron, Scott
    Infante, Jeffrey R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
    Muik, Alexander
    Garralda, Elena
    Altintas, Isil
    Gieseke, Friederike
    Geva, Ravit
    Ben-Ami, Eytan
    Maurice-Dror, Corinne
    Calvo, Emiliano
    LoRusso, Patricia M.
    Alonso, Guzman
    Rodriguez-Ruiz, Maria E.
    Schoedel, Kristina B.
    Blum, Jordan M.
    Sanger, Bianca
    Salcedo, Theodora W.
    Burm, Saskia M.
    Stanganello, Eliana
    Verzijl, Dennis
    Vascotto, Fulvia
    Sette, Angelica
    Quinkhardt, Juliane
    Plantinga, Theo S.
    Toker, Aras
    van den Brink, Edward N.
    Fereshteh, Mark
    Diken, Mustafa
    Satijn, David
    Kreiter, Sebastian
    Breij, Esther C. W.
    Bajaj, Gaurav
    Lagkadinou, Eleni
    Sasser, Kate
    Tureci, Ozlem
    Forssmann, Ulf
    Ahmadi, Tahamtan
    Sahin, Ugur
    Jure-Kunkel, Maria
    Melero, Ignacio
    CANCER DISCOVERY, 2022, 12 (05) : 1248 - 1265
  • [10] FIRST-IN-HUMAN PHASE I/IIA TRIAL TO EVALUATE THE SAFETY AND INITIAL CLINICAL ACTIVITY OF DUOBODY®-PD-L1x4-1BB (GEN1046) IN PATIENTS WITH ADVANCED SOLID TUMORS
    Garralda, Elena
    Geva, Ravit
    Ben-Ami, Eytan
    Maurice-Dror, Corinne
    Calvo, Emiliano
    LoRusso, Patricia
    Tuereci, Oezlem
    Niewood, Michelle
    Sahin, Ugur
    Jure-Kunkel, Maria
    Forssmann, Ulf
    Ahmadi, Tahamtan
    Melero, Ignacio
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A250 - A251
12345